Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT04096417	TitlePemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	Phase Phase 2	Date Added 2019-09-19	Location Arizona, United States Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Pemigatinib	Tags MSS/ MMRp
NCT ID NCT04092673	TitleStudy of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies	Phase Phase 1	Date Added 2019-09-17	Location California, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs eFT226, eFT226	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04085185	TitleA Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors	Phase Phase 1	Date Added 2019-09-11	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs IBI110, IBI110+ Sintilimab, IBI110, Sintilinab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04062721	TitleLocal Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases	Phase Phase 1	Date Added 2019-08-20	Location France	Prior IO Allowed Yes	CRC-directed Yes	Status Not yet recruiting	Drugs Chemotherapy, In situ immunotherapy	Tags MSS/ MMRp
NCT ID NCT04050709	TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	Phase Phase 1	Date Added 2019-08-08	Location California, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs PD-L1 t-haNK	Tags MSS/ MMRp
NCT ID NCT04046445	TitlePhase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer	Phase Phase 1	Date Added 2019-08-06	Location Arizona, United States California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States Belgium Germany Switzerland	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs ATP128, BI 754091, VSV-GP128	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04041310	TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors	Phase Phase 1, Phase 2	Date Added 2019-08-01	Location California, United States Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd
NCT ID NCT04017650	TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2019-07-12	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, encorafenib, Nivolumab	Tags MSS/ MMRp
NCT ID NCT04014530	TitlePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study	Phase Phase 1	Date Added 2019-07-10	Location Netherlands	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Ataluren + Pembrolizumab, Keytruda	Tags MSS/ MMRp
NCT ID NCT04009681	TitleA Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2019-07-05	Location Arizona, United States Colorado, United States Florida, United States Tennessee, United States Texas, United States Argentina Australia Chile Singapore Spain	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs anti-EGFR antibody, Checkpoint inhibitor, THOR-707	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 171 to 180 of 299 entries